



April 26, 2023

Company name: TMS Co., Ltd.  
Name of representative: Takuro Wakabayashi, CEO  
(Securities code: 4891; Growth Market)  
Inquiries: Go Ito, CFO  
(Telephone: +81-42-307-7480)

### **Notice regarding the development of TMS-007**

TMS Co., Ltd. (the “Company”) hereby announces that Biogen, Inc. (“Biogen”) announced that it is pausing initiation of TMS-007/BIIB131 Phase 2b study in acute ischemic stroke as Biogen reassesses whether to initiate the study during Biogen’s 2023 First Quarter Earnings Call held at 9pm Japan Time on April 25 (8am Eastern Day Time on the same day).

The related information can be found in Biogen’s [“Q1 2023 Biogen Earnings Presentation”](#) available at Biogen’s website.

The Company is collecting further information to assess the implications and impact of the Biogen’s decision and will promptly announce the analysis once it becomes available.

End